Showing results (11-20 of 154) with videos related to
Sort By:
Pageof 16
Leukemia Research|February 18, 2006
Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?Hans Carl Hasselbalch, Caroline H RileyClinical Case Reports|July 18, 2015
The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasmsMads Emil Bjørn, Hans Carl HasselbalchExpert Review of Hematology|May 22, 2015
Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?Hans Carl Hasselbalch, Richard T SilverSeminars in Immunopathology|September 12, 2018
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?Hans Carl Hasselbalch, Morten Orebo HolmströmEuropean Journal of Haematology|September 19, 2015
Smoking and philadelphia-negative chronic myeloproliferative neoplasmsAnders Lindholm Sørensen, Hans Carl HasselbalchLeukemia|April 8, 2026
A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alphaRichard T Silver, Hans Carl HasselbalchUgeskrift for Laeger|July 31, 2003
[Immunosuppressive treatment of the myelodysplastic syndrome]Mathilde Skaarup Larsen, Hans Carl HasselbalchCurrent Drug Targets|February 20, 2007
The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disordersHans Carl Hasselbalch, Caroline H RileySeminars in Immunopathology|July 11, 2018
Cancer immune therapy for myeloid malignancies: present and futureMorten Orebo Holmström, Hans Carl HasselbalchExpert Review of Hematology|April 13, 2017
Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinibMads Emil Bjørn, Hans Carl HasselbalchPageof 16